These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 19689309)

  • 41. Arousal and reward: a dichotomy in orexin function.
    Harris GC; Aston-Jones G
    Trends Neurosci; 2006 Oct; 29(10):571-7. PubMed ID: 16904760
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypocretin ligand deficiency in narcolepsy: recent basic and clinical insights.
    Ritchie C; Okuro M; Kanbayashi T; Nishino S
    Curr Neurol Neurosci Rep; 2010 May; 10(3):180-9. PubMed ID: 20425033
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hypocretin (orexin) receptor subtypes differentially enhance acetylcholine release and activate g protein subtypes in rat pontine reticular formation.
    Bernard R; Lydic R; Baghdoyan HA
    J Pharmacol Exp Ther; 2006 Apr; 317(1):163-71. PubMed ID: 16352704
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The orexin/hypocretin system: a critical regulator of neuroendocrine and autonomic function.
    Ferguson AV; Samson WK
    Front Neuroendocrinol; 2003 Jul; 24(3):141-50. PubMed ID: 14596809
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Roles of the hypocretin/orexins in the regulation of sleep and wakefulness.
    Terao A; Haruyama T; Kimura K
    Jpn J Vet Res; 2008 Jan; 55(2-3):75-83. PubMed ID: 18318109
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Behavioral state instability in orexin knock-out mice.
    Mochizuki T; Crocker A; McCormack S; Yanagisawa M; Sakurai T; Scammell TE
    J Neurosci; 2004 Jul; 24(28):6291-300. PubMed ID: 15254084
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The hypocretin/orexin system: an increasingly important role in neuropsychiatry.
    Chen Q; de Lecea L; Hu Z; Gao D
    Med Res Rev; 2015 Jan; 35(1):152-97. PubMed ID: 25044006
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Orexin: a link between energy homeostasis and adaptive behaviour.
    Sakurai T
    Curr Opin Clin Nutr Metab Care; 2003 Jul; 6(4):353-60. PubMed ID: 12806206
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Narcolepsy: new understanding of irresistible sleep.
    Krahn LE; Black JL; Silber MH
    Mayo Clin Proc; 2001 Feb; 76(2):185-94. PubMed ID: 11213307
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog.
    Fujiki N; Yoshida Y; Ripley B; Mignot E; Nishino S
    Sleep; 2003 Dec; 26(8):953-9. PubMed ID: 14746374
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypocretin-1 (orexin A) prevents the effects of hypoxia/hypercapnia and enhances the GABAergic pathway from the lateral paragigantocellular nucleus to cardiac vagal neurons in the nucleus ambiguus.
    Dergacheva O; Philbin K; Bateman R; Mendelowitz D
    Neuroscience; 2011 Feb; 175():18-23. PubMed ID: 21134420
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hypocretin/orexin, sleep and narcolepsy.
    Hungs M; Mignot E
    Bioessays; 2001 May; 23(5):397-408. PubMed ID: 11340621
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Polymorphisms in hypocretin/orexin pathway genes and narcolepsy.
    Olafsdóttir BR; Rye DB; Scammell TE; Matheson JK; Stefánsson K; Gulcher JR
    Neurology; 2001 Nov; 57(10):1896-9. PubMed ID: 11723285
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Electrical signaling in central orexin/hypocretin circuits: tuning arousal and appetite to fit the environment.
    Burdakov D
    Neuroscientist; 2004 Aug; 10(4):286-91. PubMed ID: 15271256
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.
    Peyron C; Faraco J; Rogers W; Ripley B; Overeem S; Charnay Y; Nevsimalova S; Aldrich M; Reynolds D; Albin R; Li R; Hungs M; Pedrazzoli M; Padigaru M; Kucherlapati M; Fan J; Maki R; Lammers GJ; Bouras C; Kucherlapati R; Nishino S; Mignot E
    Nat Med; 2000 Sep; 6(9):991-7. PubMed ID: 10973318
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Narcolepsy: pathophysiology and pharmacology.
    Nishino S
    J Clin Psychiatry; 2007; 68 Suppl 13():9-15. PubMed ID: 18078360
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aspects of the narcolepsy-cataplexy syndrome in O/E3-null mutant mice.
    De La Herrán-Arita AK; Zomosa-Signoret VC; Millán-Aldaco DA; Palomero-Rivero M; Guerra-Crespo M; Drucker-Colín R; Vidaltamayo R
    Neuroscience; 2011 Jun; 183():134-43. PubMed ID: 21435382
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reply to 'Promotion of sleep by targeting the orexin system in rats, dogs and humans'.
    Tafti M
    Nat Med; 2007 May; 13(5):525-6; author reply 526. PubMed ID: 17479088
    [No Abstract]   [Full Text] [Related]  

  • 59. The hypocretin/orexin system.
    Ebrahim IO; Howard RS; Kopelman MD; Sharief MK; Williams AJ
    J R Soc Med; 2002 May; 95(5):227-30. PubMed ID: 11983761
    [No Abstract]   [Full Text] [Related]  

  • 60. What we learned from narcolepsy of others.
    Luft FC
    J Mol Med (Berl); 2003 Feb; 81(2):69-70. PubMed ID: 12675031
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.